Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders.
Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances
Phentolamine Ophthalmic Solution 0.75% Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.